CFR section

21 CFR 314.81(b)(2)(vi)(b): Other postmarketing reports

PART 314-APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG · Subpart B-Applications

Key facts

Citation 21 CFR 314.81(b)(2)(vi)(b)
Section Other postmarketing reports
Part PART 314-APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG
Subpart Subpart B-Applications
Subchapter 21 CFR D Drugs Human
Product types cited Drugs
Regulation text (excerpt) (b) Summaries of completed unpublished clinical trials, or prepublication manuscripts if available, conducted by, or otherwise obtained by, the applicant. Supporting information should not be reported. (A study is considered completed 1 year after it is concluded.)

At a glance

  • 1–9 Inspections citing this section
  • None Warning letters citing this section

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About CFR sections cited by the FDA

Title 21 of the Code of Federal Regulations contains the FDA's regulations, including current good manufacturing practice and quality system requirements that inspections cite.

Source: U.S. Code of Federal Regulations (eCFR); citation statistics from FDA inspection and warning-letter data

Browse all CFR sections cited by the FDA